CHAPEL HILL, N.C -- It's one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...

Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of ...

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...

Long-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone. Adding Optune to temozolomide improved overall survival (OS) by ...

LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...

A head patch device that delivers alternating electrical fields to the brain has been shown to significantly improve survival in newly diagnosed glioblastoma patients. Developed by Jersey, US-based ...

It’s one of the most lethal cancers, and it affects about 20,000 Americans a year. Glioblastoma is an aggressive, fast-growing brain tumor. While there are treatments for glioblastoma, there is no ...